NCT01518244View on ClinicalTrials.gov

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Glaucoma
Interventions
DRUG

Brinzolamide/timolol maleate fixed combination

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01518244 - Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America | Biotech Hunter | Biotech Hunter